Quantcast

Latest Peripheral membrane proteins Stories

2011-02-02 06:30:00

NES-ZIONA, Israel, Feb. 2, 2011 /PRNewswire/ -- PROLOR Biotech, Inc., (NYSE Amex: PBTH), today reported positive results from a comparative study of its biobetter longer-acting version of the hemophilia drug Factor IX (Factor IX-CTP) in Factor IX-depleted hemophilic mice. The study was designed to measure the potential increase in clotting activity and duration of therapeutic effect of PROLOR's long-acting CTP-modified Factor IX when compared with commercially available recombinant...

2011-01-21 16:15:34

Mystery of 'inactive' defensin solved Under standard laboratory conditions, the human beta-defensin 1 (hBD-1), a human antibiotic naturally produced in the body, had always shown only little activity against microbes. Nevertheless the human body produces it in remarkable quantities. The solution to the puzzle was the investigation process itself, as the research group led by Dr. Jan Wehkamp at the Dr. Margarete Fischer-Bosch Institute for Clinical Pharmacology of the Stuttgart-based Robert...

2011-01-19 14:45:22

Breakthrough suggests damaged proteins travel between cells The study, published in the Journal of Clinical Investigation, reveals that damaged alpha-synuclein proteins (which are implicated in Parkinson's disease) can spread in a 'prion-like' manner, an infection model previously described for diseases such as BSE (mad cow disease). "This is a significant step forward in our understanding of the potential role of cell-to-cell transfer of alpha-synuclein in Parkinson's disease pathogenesis...

2011-01-03 21:12:55

Study is first to pinpoint the precise anatomical location where vision loss appears to occur in glaucoma In a study published today in the Proceedings of the National Academy of Sciences (Early Edition ahead of print), a team of researchers from the Kennedy Krieger Institute and four collaborating institutions, identified a new and unexpected biological pathway that appears to contribute to the development of glaucoma and its resulting vision loss. Prior research has suggested that the optic...

2010-12-16 11:21:00

VIENNA, December 16, 2010 /PRNewswire/ -- With a grant of USD 475,000, the Michael J. Fox Foundation is funding preclinical development of a vaccine against Parkinson's disease by AFFiRiS AG. The vaccine, known as PD01, targets the protein alpha-synuclein and might offer for the first time a possibility for a treatment that can slow or stop the progression of Parkinson's disease. The basis of PD01 is the company's AFFITOME(R) technology, which already delivered, among others, two vaccines...

2010-12-16 07:30:00

SOUTH SAN FRANCISCO, Calif., Dec. 16, 2010 /PRNewswire/ -- Catalyst Biosciences, Inc., the leading company in the discovery and development of engineered proteases, today announced the receipt of a $4.0 million milestone payment from Pfizer Inc. under the terms of the collaboration agreement for the development of improved recombinant human Factor VIIa variants for the treatment of hemophilia and other bleeding disorders. "We are very encouraged by the progress made to date in our...

2010-12-08 08:00:00

CRANBURY, N.J., Dec. 8, 2010 /PRNewswire/ -- Amicus Therapeutics (Nasdaq: FOLD), a biopharmaceutical company focused on developing treatments for rare diseases, today announced that it has been awarded a second grant from The Michael J. Fox Foundation for Parkinson's Research (MJFF) for the development of a novel, next-generation pharmacological chaperone for the treatment of Parkinson's disease. The $500,000 award will be distributed over a period of 24 months. Amicus' studies will be...

2010-12-08 02:23:15

A Purdue University research team developed a nanoparticle that can hold and release an antimicrobial agent as needed for extending the shelf life of foods susceptible to Listeria monocytogenes. Yuan Yao, an assistant professor of food science, altered the surface of a carbohydrate found in sweet corn called phytoglycogen, which led to the creation of several forms of a nanoparticle that could attract and stabilize nisin, a food-based antimicrobial peptide. The nanoparticle can then preserve...

2010-12-01 07:30:00

KING OF PRUSSIA, Pa., Dec. 1, 2010 /PRNewswire/ -- CSL Behring announced today the availability of the next generation HeliTrax® System as part of a specially designed software platform for Apple's iPhone®, iPod touch®, or iPad(TM) devices. This enhanced system is designed to improve therapy management for people with hemophilia A who use CSL Behring's recombinant factor VIII (rFVIII). The new HeliTrax software is designed with an...

2010-11-19 00:30:00

LAGUNA NIGUEL, Calif., Nov. 19, 2010 /PRNewswire/ -- Inspiration Biopharmaceuticals, Inc. (Inspiration) today announced the Company has initiated treatment of patients in a pivotal clinical study of OBI-1, an intravenous recombinant porcine factor VIII (FVIII) product, for the treatment of acquired hemophilia A, a rare, though potentially life-threatening bleeding disorder. Based on a partnership agreement signed with Ipsen SA (Euronext: IPN; ADR: IPSEY) in January 2010, Inspiration has...


Latest Peripheral membrane proteins Reference Libraries

Paneth Cells
2012-07-01 19:03:07

Paneth Cells are one of four principal cell types found in the epithelium of the small intestine; the other three are the goblet cell, enterocyte, and enteroendocrine cell. Paneth cells may also be found in the cecum and appendix, although sporadically. These cells are identifiable microscopically by their location just below the intestinal stem cells in the intestinal glands. and the large eosinophilic refractile granules that occupy most of their cytoplasm. These granules consist of...

More Articles (1 articles) »
Word of the Day
lambent
  • Licking.
  • Hence Running along or over a surface, as if in the act of licking; flowing over or along; lapping or bathing; softly bright; gleaming.
This word comes the Latin 'lambere,' to lick.
Related